PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
285.71%
Net income growth above 1.5x VET's 71.92%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-0.49%
Both reduce yoy D&A, with VET at -36.59%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
170.53%
Some yoy growth while VET is negative at -66.34%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
-16200.00%
Both reduce yoy usage, with VET at -17.62%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16200.00%
Negative yoy usage while VET is 0.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-79.06%
Negative yoy while VET is 86420.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-31.12%
Both yoy CFO lines are negative, with VET at -0.45%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-18.42%
Both yoy lines negative, with VET at -45.56%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
130.90%
Acquisition growth of 130.90% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3142.11%
We reduce yoy other investing while VET is 291.46%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
18.54%
We have mild expansions while VET is negative at -26.57%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.